Mineralys Therapeutics Overview
Mineralys Therapeutics (MLYS) has a ROE of -63.45%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-63.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for MLYS is -63.45%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Mineralys Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, MLYS currently prints -63.45% for ROE, while the sector average sits near -5.68%. That is roughly 1016.5% below the sector mean. Large gaps often invite a closer look at Mineralys Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Mineralys Therapeutics converts resources into returns. At -63.45%, MLYS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting MLYS's ROE (-63.45%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
